About Marie Guillou

This author has not yet filled in any details.
So far Marie Guillou has created 390 blog entries.

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I.

2024-09-26T14:22:35+02:00

 J Eur Acad Dermatol Venereol. 2021 Sep European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology [...]

European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I.2024-09-26T14:22:35+02:00

Mucous Membrane Pemphigoid guidelines – guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by EADV – Part I.

2024-09-16T14:54:02+02:00

Mucous Membrane Pemphigoid guidelines –  guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I. [...]

Mucous Membrane Pemphigoid guidelines – guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by EADV – Part I.2024-09-16T14:54:02+02:00

Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus

2024-09-16T14:28:52+02:00

Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus

Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus2024-09-16T14:28:52+02:00

Webinar EB – Join the Meeting

2021-06-29T17:39:48+02:00

ERN-Skin Webinar Combined cell and gene therapy for Epidermolysis Bullosa – Michele De Luca Chaired by Cristina Has (Freiburg) / Christine Bodemer (Paris) [...]

Webinar EB – Join the Meeting2021-06-29T17:39:48+02:00

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)

2024-09-26T14:24:46+02:00

J Eur Acad Dermatol Venereol. 2021 Jun;35(6):1251-1277 S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology [...]

S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV)2024-09-26T14:24:46+02:00

Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by EADV

2024-09-16T14:55:45+02:00

Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV).

Dermatitis herpetiformis guidelines – S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by EADV2024-09-16T14:55:45+02:00

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study

2024-10-01T10:49:47+02:00

Publication - Epub 2020 Sep 16. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study [...]

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study2024-10-01T10:49:47+02:00